FeesSafety
Pluang+

Ethereum Foundation swaps 1,200 ETH for stablecoins, boosting sUSDS holdings to $34.47M

Protocol Fundamentals
19 Nov 2026, 03:09 WIB
Tokenpost
View Source
Neutral
Ethereum Foundation swaps 1,200 ETH for stablecoins, boosting sUSDS holdings to $34.47M

The Ethereum Foundation exchanged 1,200 Ether (ETH) for USDS and sUSDS stablecoins via CoWSwap, increasing its sUSDS balance to 30.78 million, worth about $34.47 million as of November 19. This swap was valued at approximately $2.14 million. The foundation also deposited 1.777 million USDS into the SkyMoney savings contract, receiving 1.591 million sUSDS, which earns returns through Sky's variable savings rate. Previously, the foundation exchanged 7,500 ETH for about 14.52 million USDS over four days, indicating ongoing asset management and diversification strategies.

The Ethereum Foundation's recent swap activity involved exchanging 1,200 Ether for USDS and sUSDS stablecoins, increasing its sUSDS holdings to about $34.47 million as of November 19, 2026. For readers following the cryptocurrency market, here is Pluang's market snapshot as of Nov 19, 2026 07:12 WIB: out of 50 major cryptocurrencies, 9 rose and 40 fell. Notable movers include XNO (Nano) with a 1-day change of +3.72% and Pluang order activity of 45% Sell / 55% Buy, BTC (Bitcoin) down 3.69% with 22% Sell / 78% Buy, and AVAX (Avalanche) down 3.66% with 6% Sell / 94% Buy.

More News

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron Technology is showing strong financial growth, driven by its crucial role in AI infrastructure and multiyear deals with key tech companies. The company recently beat revenue expectations with a 379% year-over-year increase and projects even be...

Company Fundamentals
Bullish
1 hour ago
FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

The FDA has approved Livsayis™ (cemdisiran), the first and only siRNA therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive. This subcutaneous treatment, administered four times a year, targ...

Market News
Bullish
1 hour ago
Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Elauwit announced a 66% year-over-year increase in monthly recurring revenue to $539,000 by the end of Q3 2026, driven by long-term contracts for managed Wi-Fi in apartment communities. The company also reduced operating expenses by 19% sequentially ...

Company Fundamentals
Bullish
1 hour ago
Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Montauk Renewables deferred up to $120 million in capital spending and is negotiating credit facility amendments due to operational delays at its North Carolina swine waste project. These delays have created short-term risks for debt covenants, requi...

Company Fundamentals
Neutral
1 hour ago
Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir Technologies has shown rapid quarter-over-quarter revenue growth, reaching $2.3 billion in Q3 2026, driven by strong commercial adoption of its AI platform and expansion beyond government contracts. In contrast, UiPath's revenue growth is mo...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App